ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Pulmonary Disease

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,461Medicare Part D Prescriptions Filled, Including Refills

Rank: 1 out of 26

$565K Total Retail Price of All Prescriptions

Rank: 3 out of 26

285 Patients Receiving at Least One Drug in Part D
70%Patients 65 Years and Older
72% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Delaware
Lower avg

Schedule Two
Controlled Substances

6% of this provider’s 285 patients filled at least one prescription for a schedule two drug, compared to an average of 0%.

Schedule Three
Controlled Substances

7% of this provider’s 285 patients filled at least one prescription for a schedule three drug, compared to an average of 0%.

Risky Drugs to Seniors

1% of this provider’s 5,607 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 0%.

Brand Name Drugs

25% of this provider’s prescriptions were for brand-name drugs, compared to an average of 68%.

Prescription Price

$67 was the average price of a prescription from this provider, compared to $211 among peers.

Prescriptions per Patient

30 is the average number of prescriptions (including refills) per patient, compared to an average of 8.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Delaware
LISINOPRIL 351 234 1 8
LEVOTHYROXINE SODIUM 326 241 2 10
SIMVASTATIN 290 229 3 12
METFORMIN HCL 263 147 4 13
OMEPRAZOLE 256 144 5 6
AMLODIPINE BESYLATE 239 213 6 15
FUROSEMIDE 203 128 7 16
METOPROLOL TARTRATE 191 122 8 17
TRAMADOL HCL 159 82 9 19
LEVETIRACETAM 135 40 10 21
PROAIR HFA 121 63 11 3
NEXIUM 113 70 12 24
GLIPIZIDE 103 61 13 27
HYDRALAZINE HCL 102 92 14 28
FELODIPINE ER 100 76 15 29
METOPROLOL SUCCINATE 96 88 16 30
CARBIDOPA-LEVODOPA 90 90 17 31
PRAVASTATIN SODIUM 89 28 18 32
RANITIDINE HCL 89 69 18 32
TAMSULOSIN HCL 85 57 20 34
SPIRIVA 85 59 20 1
CLONIDINE HCL 84 71 22 35
ATORVASTATIN CALCIUM 82 67 23 36
CRESTOR 81 46 24 37
ADVAIR DISKUS 79 64 25 2
TRICOR 74 40 26 39
PREDNISONE 74 53 26 4
HYDROCODONE-ACETAMINOPHEN 73 52 S3 28 40
DONEPEZIL HCL 72 68 29 41
SERTRALINE HCL 72 60 29 41
CLOPIDOGREL 65 47 31 43
RAMIPRIL 65 23 31 43
LAMOTRIGINE 65 51 31 43
HYDROCHLOROTHIAZIDE 64 57 34 46
PLAVIX 63 44 35 47
AZITHROMYCIN 63 43 35 11
WARFARIN SODIUM 61 38 37 48
ALLOPURINOL 58 34 38 49
AVODART 57 43 39 50
CYCLOBENZAPRINE HCL 57 11 R 39 50
DIVALPROEX SODIUM ER 54 21 41 52
VYTORIN 54 34 41 52
GABAPENTIN 53 45 43 54
BACLOFEN 53 0 43 54
LOSARTAN POTASSIUM 52 48 45 56
TRAZODONE HCL 50 36 46 57
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Nov. 29, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.